Deal Snapshot: Innate will receive €25m up front from Sanofi for an exclusive license to a new natural killer (NK) cell engager program and options to two additional targets.
Who: Sanofi and Innate Pharma S.A.
What: Sanofi gains an exclusive license to develop and commercialize Innate's natural killer (NK) cell engager program targeting B7H3 from...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.
Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.
Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.
Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.
US green light will further expand sales of the prostate cancer blockbuster.
Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
